US FDA approves Lupkynis (voclosporin)

More great news for people with lupus! The U.S. Food and Drug Administration (FDA) has approved Lupkynis™ (voclosporin) to treat lupus nephritis (lupus-related kidney disease) in adults when used in combination with a background immunosuppressive therapy regimen. Lupkynis is the second new therapy authorized to treat this potentially life-threatening complication of lupus. Developed by Aurinia…

Details

US FDA approve Benlysta

GSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA The U.S. Food and Drug Administration (FDA) in late December 2020 approved Benlysta® to treat lupus nephritis (lupus-related kidney disease) in adults. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease. Another milestone, this new…

Details

Phase 3 Trial – Benlysta

Phase 3 Trial Finds Benlysta Significantly Improves Kidney Response in People with Lupus Nephritis UPDATE 16/09/2020 In new results on the international phase 3 clinical trial (BLISS-LN) of the drug Benlysta (belimumab), researchers found that Benlysta reduced the risk of worsening kidney function during the study by almost 50%, compared with standard therapy alone. The…

Details

Update – Access to Hydroxychloroquine

Access to Hydroxychloroquine for People with Lupus The Lupus Association of NSW is aware of the potential use of hydroxychloroquine and chloroquine for the treatment of coronavirus (COVID-19). This means that some people with Lupus who use hydroxychloroquine to manage their condition are having difficulty accessing this medication. Hydroxychloroquine, a medication taken by approximately 90% of…

Details

COVID-19 & Access to Hydroxychloroquine

COVID-19 & Access to Hydroxychloroquine At present the trials are ongoing and there isn’t sufficient evidence to conclude whether it will be effective. Science Magazine stated that the available evidence that chloroquine and hydroxychloroquine work against COVID-19 was ‘thin’. The U.S. Society of Critical Care Medicine said “there is insufficient evidence to issue a recommendation…

Details

Inactivity, Isolation and Impact on Daily Life are Top Concerns for People Living with Lupus

World Lupus Federation issues global report for World Lupus Day highlighting the life-altering effects of lupus and the challenges people with lupus face every day. WASHINGTON, May 9, 2017 /PRNewswire-USNewswire/ — Almost half (43%) of people living with lupus responding to a recent poll* indicated that they worry the most about physical inactivity and social isolation…

Details